Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple scler
Author: ["Bibiana Bielekova","Bonnie Goodwin","Nancy Richert","Irene Cortese","Takayuki Kondo","Ghazaleh Afshar","Bruno Gran","Joan Eaton","Jack Antel","Joseph A. Frank","Henry F. McFarland","Roland Martin"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Myelin-specific T lymphocytes are considered essential in the pathogenesis of multiple sclerosis. The myelin basic protein peptide (a.a. 83–99) represents one candidate antigen; therefore, it was chosen to design an altered peptide ligand, CGP77116, for specific immunotherapy of multiple sclerosis. A magnetic resonance imaging-controlled phase II clinical trial with this altered peptide ligand documented that it was poorly tolerated at the dose tested, and the trial had therefore to be halted. Improvement or worsening of clinical or magnetic resonance imaging parameters could not be demonstrated in this small group of individuals because of the short treatment duration. Three patients developed exacerbations of multiple sclerosis, and in two this could be linked to altered peptide ligand treatment by immunological studies demonstrating the encephalitogenic potential of the myelin basic protein peptide (a.a. 83–99) in a subgroup of patients. These data raise important considerations for the use of specific immunotherapies in general.
Cite this article
Bielekova, B., Goodwin, B., Richert, N. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 6, 1167–1175 (2000). https://doi.org/10.1038/80516
